Opioid formulations
AssigneeCamurus AB
InventorsFredrik Tiberg, Ian Harwigsson, Markus Johnsson
Life of this patent
Estimating the term…
Abstract
A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
Claims30
A depot precursor formulation comprising:
- a) a lipid controlled release formulation comprising i) phosphatidylcholine and ii) glycerol dioleate, wherein the phosphatidylcholine is about 10 to about 25% by weight of the total weight of the depot precursor formulation, and the glycerol dioleate is about 15 to about 25% by weight of the total weight of the depot precursor formulation;
- b) about 25 to about 32% by weight of N-methyl-2-pyrrolidone;
- and
- c) about 25 to about 50% by weight of buprenorphine.
A method of administering an opioid maintenance treatment to a subject, the method comprising administering a depot precursor formulation once monthly to the subject, wherein the depot precursor formulation comprises:
- a) a lipid controlled release formulation comprising i) phosphatidylcholine and ii) glycerol dioleate, wherein the phosphatidylcholine is about 10 to about 25% by weight of the total weight of the depot precursor formulation, and the glycerol dioleate is about 15 to about 25% by weight of the total weight of the depot precursor formulation;
- b) about 25 to about 32% by weight of N-methyl-2-pyrrolidone;
- and
- c) about 25 to about 50% by weight of buprenorphine.
Dependencies are inferred from the claim text.